- Companies
- Color
Color Valuation, Funding & Investors
Color is valued at $4.6B as of November 2021.
Last Color valuation
$4.6B
Series E · Nov 2021
Last Color funding round
$100M
Series E · Nov 2021
Cumulative funding Color raised
$482M
across 6 funding rounds
Key investors in Color
General Catalyst
T. Rowe Price
Viking Global Investors
Emerson Collective
Khosla Ventures
Initialized Capital
About Color
Color is a health technology platform delivering population genomics, cancer screening, and COVID-19 testing programs for employers, schools, and governments. Headquartered in Burlingame, California, it processes whole-genome sequencing through CLIA-certified labs and partners with health systems like Kaiser Permanente for nationwide deployment.
Founded
2013
HQ
Website
Status
Privately held
Customer focus
B2B & B2G
Revenue model
Services
Valuation
$4.6B (Nov 2021)
Color Valuation
Color is currently valued at $4.6B, based on its Series E in November 2021.
The $100M round was led by Kindred Ventures and T. Rowe Price, with participation from General Catalyst, Emerson Collective, Viking Global Investors and WR Hambrecht.
Color's valuation has grown 3.1x from $1.5B at its Series D in January 2021 to $4.6B in November 2021, across 2 priced rounds.
Color valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Nov 2021 | Series E | $4.6B |
| Jan 2021 | Series D | $1.5B |
Color Funding History
Color has raised a total of $482M across 6 funding rounds.
Color's first fundraising round was a $15M Series A in April 2015. The most recent completed round was a $100M Series E in November 2021.
Color funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Nov 2021 | Series E | Kindred Ventures (lead); T. Rowe Price (lead); General Catalyst; Emerson Collective; Viking Global Investors; WR Hambrecht | $100M | $4.6B | Color, a San Francisco-based health technology company founded in 2015 as Color Genomics, provides population-scale healthcare programs including preventive health, genetic testing, infectious disease management, COVID-19 testing, and vaccinations. It partners with over 1,000 organizations such as employers, universities, public health departments, Salesforce, the National Institutes of Health, the State of California, and Thermo Fisher Scientific, operating more than 6,500 testing sites and 500 vaccination sites. On November 9, 2021, Color raised $100 million in a Series E funding round led by Kindred Ventures and funds managed by T. Rowe Price Associates, with participation from General Catalyst, Viking Global Investors, Emerson Collective, and WR Hambrecht implied in investor lists. The post-money valuation reached $4.6 billion, tripling the $1.5 billion from its January 2021 Series D round of $167 million, bringing total funding to $378 million. Proceeds will expand public health infrastructure for screening, diagnosis, treatment, and last-mile care delivery beyond COVID-19 into broader healthcare services. Color's CFO described the business as strong, sustainable, and profitable, emphasizing scalable execution amid U.S. health challenges. The company pivoted during the pandemic from whole-genome sequencing to large-scale COVID testing and vaccines, now targeting primary care and equitable access via tech-enabled tools for at-home and on-site services. This positions Color among top health care unicorns, building on prior rounds led by General Catalyst. |
| Jan 2021 | Series D | General Catalyst (lead); T. Rowe Price (lead); Viking Global Investors | $167M | $1.5B | Color is a health technology company founded in 2015, initially focused on genomics services including whole-genome sequencing and genetic counseling, which expanded during the COVID-19 pandemic into telehealth, health data management, COVID testing, and vaccine delivery programs. The company announced a $167 million Series D funding round in early January 2021, valuing it at $1.5 billion post-money and bringing total funding to $278 million. The round was led by General Catalyst with participation from Viking Global Investors and funds managed by T. Rowe Price, marking the first official disclosure of Color's unicorn status as prior rounds had not publicized valuations. Color's platform builds infrastructure for public health programs, partnering with over 100 major employers and universities for COVID testing, which received FDA emergency authorization for at-home use. By 2021, it managed testing for employers, schools, and public health departments, positioning itself as a key player in decentralized healthcare delivery amid pandemic challenges. The funding supported expansion into a national technology-based public health infrastructure, leveraging lessons from the U.S. health system's COVID response. Later in November 2021, Color raised $100 million in a Series E round at a $4.6 billion valuation, led by Kindred Ventures and T. Rowe Price with participation from General Catalyst, Viking, and Emerson Collective, tripling its prior valuation and funding further growth into primary care services beyond COVID and genetic testing. The company facilitated over 6,500 testing sites and 500 vaccination sites nationwide. Color's CFO described the business as strong, sustainable, and profitable, though specific revenue or EBITDA figures were not disclosed for the 2021 Series D. |
| Jan 2020 | Series D | T. Rowe Price (lead); Viking Global Investors (lead) | $75M | - | Color is a health technology company based in Burlingame, California, specializing in population-scale healthcare programs, clinical testing, telehealth, and software infrastructure for preventative care, infectious disease management, and precision genomics, enabling services directly at workplaces or communities. The company raised a $75 million funding tranche in January 2020 led by funds advised by T. Rowe Price Associates and Viking Global Investors, which was later incorporated into a larger $167 million Series D round announced in early 2021 led by General Catalyst, bringing total financing to $278 million at that time. This 2020 raise supported scaling a sustainable business following more than seven-times contract growth and improved profitability, with focus on genomic infrastructure and clinical care expansion. The $1.5 billion valuation was announced with the full Series D completion. Color had previously raised an $80 million Series C in 2017. The funding aligned with growing demand amid public health challenges, including COVID-19 testing programs for employers, schools, and vaccine distribution. Post-2020, Color continued raising capital, including a $100 million Series E in late 2021 at a $4.6 billion valuation, led by Kindred Ventures with participation from T. Rowe Price, General Catalyst, Viking Global Investors, and Emerson Collective, to expand virtual oncology, AI diagnostics, and public health infrastructure. The company became a key player in U.S. COVID-19 testing, running the largest K-12 school program, and shifted toward broader healthcare services. Total funding exceeded $496 million across multiple rounds by 2022. |
| Aug 2017 | Series C | General Catalyst (lead); Emerson Collective; Jaws Ventures; LionTree; Pegasus Tech Ventures; LeFrak; CRV | $80M | - | Color is a Burlingame, California-based health technology company founded in 2015 as Color Genomics, specializing in population-scale healthcare programs including genetic testing, COVID-19 testing, screening, diagnostics, and treatments for employers, governments, schools, and health departments. It has partnerships with organizations like Thermo Fisher Scientific, Salesforce, and the State of California, operating over 6,500 testing and 500 vaccination sites across the US. The company focuses on cost-efficient infrastructure for telehealth, preventative care, and infectious disease management directly at workplaces and communities. The queried 2017 funding round matches references to an approximately $80-90M Series C (possibly in multiple tranches: Series C, C-II, C-III), reportedly led by General Catalyst with participation from Emerson Collective and others. Earlier, Color raised a $45M Series B in 2016 led by General Catalyst with Emerson Collective, Khosla Ventures, 8VC, Susan Wagner, and Bono, following a $15M Series A led by Khosla in 2015. Subsequent rounds include a $167M Series D in January 2021 at $1.5B post-money valuation led by General Catalyst with T. Rowe Price and Viking Global Investors, bringing total raised to $278M at that time, aimed at expanding US health infrastructure including COVID-19 vaccines. In November 2021, a $100M Series E led by Kindred Ventures valued Color at $4.6B post-money, with T. Rowe Price, General Catalyst, Emerson Collective, and Viking Global, increasing total funding to $378M (or $496M per some trackers) for enhancing screening and treatment capacity. General Catalyst participated across multiple rounds including Series B (2016), C (2017), D (2021), and E (2021). Color experienced significant growth during the COVID-19 pandemic, tying up with nearly 1,000 organizations. |
| Sep 2016 | Series B | General Catalyst (lead) | $45M | - | - |
| Apr 2015 | Series A | Initialized Capital; AME Cloud Ventures; Formation 8; Avichal Garg; Khosla Ventures; Katie Stanton; Drew Houston; Julia Hartz; Chloe Sladden; Ben Davenport; Aaron Levie; #Angels | $15M | - | - |
Who has invested in Color?
23 investors have backed Color across its funding rounds, including General Catalyst, T. Rowe Price, Viking Global Investors, Emerson Collective, Khosla Ventures and Initialized Capital.
Lead investors include Kindred Ventures, T. Rowe Price, General Catalyst and Viking Global Investors.
Color Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Sep 2016 | ||
| 3 | Lead | Jan 2020 | ||
| 3 | Lead | Jan 2020 | ||
| 2 | Participant | Aug 2017 | ||
| 1 | Participant | Aug 2017 | ||
| 1 | Participant | Apr 2015 | ||
| 1 | Participant | Apr 2015 | ||
| 1 | Participant | Apr 2015 | ||
| 1 | Participant | Apr 2015 | ||
| 1 | Participant | Apr 2015 | ||
| 1 | Lead | Nov 2021 | ||
| 1 | Participant | Apr 2015 | ||
| 1 | Participant | Apr 2015 | ||
This data is available for Pro users. Sign up to see all 23 Color investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Color
Color has acquired 1 company to date.
Last acquisition by Color was on October 27th 2022. Color acquired Mood Lifters for undisclosed valuation.
Latest Acquisitions by Color
| Description | Mood Lifters is a wellness center located in Encinitas, California, offering therapy sessions blending psychology and mindfulness practices. Programs address anxiety and depression through group workshops and one-on-one counseling. Mood Lifters incorporates yoga and art therapy in beachside facilities. Opened in 2018, the center partners with local physicians for referrals. |
| HQ Country | |
| HQ City | Ann Arbor, MI |
| Deal Date | 27 Oct 2022 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Color acquisitions and their M&A valuation multiples. Start Free Trial | |
Color Competitors
Color competitors include listed companies like BillionToOne, GRAIL, Veracyte and CareDx, and private ones like Heyuan Biotechnology and Institut Merieux.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $305M | $12M | $5.2B | 11.7x | ||
| Publicly listed | $147M | ($407M) | $3.6B | 16.3x | ||
| Publicly listed | $517M | $77M | $3.3B | 4.9x | ||
| Private | - | - | $3B | - | ||
| Publicly listed | $380M | ($10M) | $2.8B | 5.3x | ||
| Private | - | - | $8.5B | - |
Color Public Comps
Color is still privately-owned, but its public comps include Wantai BioPharm, Celcuity, BillionToOne, GRAIL, Veracyte, GeneDx, CareDx, BGI Genomics, Genus and Insight Lifetech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $271M | ($24M) | 15.5x | - | (174.0x) | - | |||
| - | ($172M) | - | 163.2x | (24.2x) | (17.8x) | |||
| $305M | $12M | 15.8x | 11.7x | 401.1x | 75.4x | |||
| $147M | ($407M) | 19.0x | 16.3x | (6.9x) | (7.6x) | |||
| $517M | $77M | 5.4x | 4.9x | 36.6x | 18.0x | |||
| $428M | $7M | 7.4x | 6.8x | 477.6x | 183.5x | |||
| $380M | ($10M) | 6.5x | 5.3x | (249.3x) | 41.0x | |||
| $553M | ($20M) | 3.5x | 3.4x | (96.4x) | 42.4x | |||
This data is available for Pro users. Sign up to see all Color competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Color
| When was Color founded? | Color was founded in 2013. |
| Where is Color headquartered? | Color is headquartered in San Francisco, CA, United States. |
| Is Color publicly listed? | No, Color is a private, VC-backed company. |
| What is Color's valuation? | Color was last valued at $4.6B in its Series E in November 2021. |
| How much funding has Color raised? | Color has raised $482M across 6 funding rounds. |
| What was Color's last funding round? | Color's last funding round was a $100M Series E in November 2021, led by Kindred Ventures and T. Rowe Price. |
| Who are Color's investors? | Color's investors include General Catalyst, T. Rowe Price, Viking Global Investors, Emerson Collective, Jaws Ventures, Initialized Capital, AME Cloud Ventures, Formation 8, Avichal Garg, Khosla Ventures and 13 others. |
| Which companies are comparable to Color? | Companies comparable to Color include BillionToOne, GRAIL, Veracyte, Heyuan Biotechnology, CareDx and Institut Merieux. |
| How many companies has Color acquired? | Color has acquired 1 company, including Mood Lifters. |
See companies similar to Color
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




